COVID-19 infection in chronic spontaneous urticaria treated with omalizumab: two case reports

Angelo Massimiliano D'Erme; Cristian Fidanzi; Marco Romanelli; Valentina Dini; Giovanni Bagnoni; Agata Janowska

doi:10.4081/dr.2023.9763

Authors

Angelo Massimiliano D'Erme
a.m.derme@gmail.com
Melanoma and Skin Cancer Unit AVNO (Area Vasta Nord Ovest) and Unit of Dermatology, Livorno Hospital, Italy.
Cristian Fidanzi Unit of Dermatology, University of Pisa, Italy. https://orcid.org/0000-0002-9189-9204
Marco Romanelli Unit of Dermatology, University of Pisa, Italy.
Valentina Dini Unit of Dermatology, University of Pisa, Italy.
Giovanni Bagnoni Melanoma and Skin Cancer Unit AVNO (Area Vasta Nord Ovest) and Unit of Dermatology, Livorno Hospital, Italy.
Agata Janowska Unit of Dermatology, University of Pisa, Italy.

Dear Editor, Chronic spontaneous urticaria (CSU) is an inflammatory skin disease characterized by itchy pomphi associated or not with angioedema and occurring with daily or near-daily frequency for more than six weeks. It is divided into two entities, an autoimmune form determined by the presence of immunoglobulin (IgG) specific for FcɛRI receptors on tissue mast cells and circulating basophils, and an idiopathic form. [...]

Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2021.

Alizadeh Aghdam M, Knol EF, van den Elzen M, et al. Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria. Clin Exp Allergy 2020;50:364-71.

Bostan E, Zaid F, Karaduman A, et al. The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study. J Cosmet Dermatol 2021;20:3369-75.

Winthrop KL, Mariette X, Silva JT, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 2018;24:S21-S40.

Passante M, Napolitano M, Dastoli S, et al. Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19. Dermatol Ther 2021;34:e15111.

Criado PR, Criado RFJ, Pincelli TP, et al. Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab. Int J Dermatol 2020;59:1294-5.

Klimek L, Pfaar O, Worm M, et al. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in cooperation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)H. Allergol Select 2020;4:53-68.

Abdelmaksoud A, Goldust M, Vestita M. Omalizumab and COVID-19 treatment: could it help?. Dermatol Ther 2020;33:e13792.

Kocatürk E, Salman A, Cherrez-Ojeda I, et al. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. Allergy 2021;76:816-30.

D’Erme, A. M., Fidanzi, C., Romanelli, M., Dini, V., Bagnoni, G., & Janowska, A. (2023). COVID-19 infection in chronic spontaneous urticaria treated with omalizumab: two case reports. Dermatology Reports, 16(2). https://doi.org/10.4081/dr.2023.9763